Recent developments include the company's Q2 2026 financial results showing an expanded net loss but reaffirmed 2026 revenue guidance, plans to submit a supplemental new drug application for selinexor, and ongoing clinical trial progress.

• Karyopharm reported Q2 2026 net loss expansion but revenue exceeded some expectations, reaffirming 2026 revenue guidance and planning a supplemental new drug application for selinexor in August 2026 [N1][N2].
• The company continues enrollment and data analysis for late-stage clinical trials in myelofibrosis and endometrial cancer, with top-line data expected in 2026 [N1].
• Karyopharm is actively evaluating financing opportunities and strategic alternatives to extend its cash runway and support ongoing operations [N1].

The company has established a commercial presence with FDA-approved indications for XPOVIO® and is advancing late-stage clinical trials in high unmet need cancers such as myelofibrosis and endometrial cancer. Successful expansion of indications and geographic markets could enhance revenue streams. The company has secured financing transactions to support ongoing operations and development programs, and is actively exploring strategic alternatives to extend its cash runway and preserve shareholder value.

Karyopharm faces significant financial challenges, including substantial accumulated deficits, ongoing net losses, and liquidity constraints with substantial doubt about its ability to continue as a going concern beyond September 2026 without additional financing. Clinical trial outcomes remain uncertain, and regulatory approvals for new indications are not guaranteed. The company is exposed to competitive pressures, potential dilution from financing, and operational risks including regulatory compliance and market acceptance.

Karyopharm's moat is based on its pioneering development of XPO1 inhibitors, a novel mechanism of action in cancer therapy, with its lead product XPOVIO® being the first oral XPO1 inhibitor approved by the FDA. The company holds regulatory approvals in multiple indications and territories, supported by clinical trial data. Its commercial infrastructure and patient support programs enhance market penetration. However, the company faces competition in oncology and must maintain intellectual property protection and regulatory compliance to sustain its competitive position.

• Liquidity and Going Concern Risk: The company has substantial doubt about its ability to continue as a going concern beyond September 2026 without additional financing or strategic alternatives. A $15.8 million principal payment due in September 2026 may trigger default if not waived or refinanced [S2].
• Operating Losses and Profitability: Karyopharm has incurred significant operating losses since inception, with a net loss of $67.0 million in Q2 2026 and an accumulated deficit of $1.8 billion. The company may never achieve or maintain profitability [S1][S2].
• Need for Additional Capital: The company requires substantial funds to maintain research, development, and commercialization activities. Adequate additional financing may not be available on acceptable terms, potentially leading to cost reductions or cessation of operations [S1][S2].
• Regulatory and Clinical Trial Risks: Success in clinical trials and regulatory approvals for new indications such as myelofibrosis and endometrial cancer is uncertain. Failure or delays could materially harm the business [S1].
• Competition and Market Acceptance: The company faces substantial competition in oncology markets. Market acceptance of XPOVIO and future products depends on pricing, reimbursement, and clinical guidelines [S1].
• Debt and Covenant Compliance: The company must comply with covenants under its credit agreements and convertible notes. Failure to do so could result in default and acceleration of debt obligations [S1][S2].

• Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company focused on novel cancer therapies targeting nuclear export via XPO1 inhibition.
• The lead product is XPOVIO® (selinexor), the first oral XPO1 inhibitor approved by the FDA in July 2019.
• XPOVIO is approved in the U.S. for multiple myeloma in combination with bortezomib and dexamethasone, for penta-refractory multiple myeloma with dexamethasone, and for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) under accelerated approval.
• The company is developing selinexor for additional indications including myelofibrosis and endometrial cancer, with ongoing Phase 3 trials (SENTRY for myelofibrosis, XPORT-EC-042 for endometrial cancer).
• Commercialization of XPOVIO in the U.S. is supported by a sales force, nurse liaisons, market access teams, and patient support programs.
• Outside the U.S., commercialization is managed by partners in various territories with approvals in 50 countries.
• The company completed enrollment in the Phase 3 SENTRY trial for myelofibrosis in September 2025 and expects top-line data in March 2026.
• A Phase 2 SENTRY-2 trial for myelofibrosis monotherapy is ongoing with expected data in the second half of 2026.
• The Phase 3 XPORT-EC-042 trial for endometrial cancer is ongoing with expected top-line data in mid-2026.
• In October 2025, the company completed financing transactions including new term loans, convertible debt, equity issuances, and warrant exchanges to provide financial flexibility.
• As of December 31, 2025, the company had an accumulated deficit of $1.8 billion and net losses of $196 million in 2025.
• For the quarter ended June 30, 2026, the company reported a net loss of $67.0 million and basic and diluted EPS of -$2.32.
• As of June 30, 2026, cash and cash equivalents were $54.98 million, current assets $106.38 million, current liabilities $134.23 million, with a current ratio of 0.79 and cash ratio of 1.11.
• The company has substantial doubt about its ability to continue as a going concern beyond September 2026 without additional financing or strategic alternatives.
• A $15.8 million principal payment on the senior secured term loan is due September 10, 2026, which may trigger default if paid without additional financing or waiver.
• The company is actively evaluating financing opportunities and strategic alternatives including potential merger, sale, restructuring, or refinancing to extend cash runway and preserve flexibility.
• Risks include continued operating losses, need for additional capital, regulatory approval uncertainties, competition, clinical trial enrollment and outcomes, and potential dilution from financing.
• The company reaffirmed 2026 revenue guidance and plans to submit a supplemental new drug application (SNDA) for selinexor in August 2026.
• Recent quarterly results showed expanded net loss but revenue that exceeded some expectations.
• The company’s commercial efforts are supplemented by specialty pharmacy networks and patient assistance programs.
• The company’s lead product XPOVIO has received regulatory approvals in multiple indications and territories, with ongoing efforts to expand indications and geographic reach.